Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line study of pembrolizumab plus carboplatin/taxane induction followed by maintenance pembrolizumab with or without MK-2870 in metastatic squamous non-small cell lung cancer
CTR20242541Phase 3Active
- Sponsor
- MSD
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab tirumotecan, pembrolizumab in Pulmonary squamous cell carcinoma, sponsored by MSD. Started Oct 2024; status: active.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20242541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242541.